DAXOR CORP (DXR) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated July 15, 2024, reports the results of Daxor Corporation's Annual Meeting of Shareholders held on that date. Daxor is a medical instrumentation and biotechnology company focused on blood volume measurement, primarily marketing the FDA-cleared BVA-100® Blood Volume Analyzer.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
The primary material event reported is the election of directors and the ratification of the independent auditor. The voting results were as follows:
- Director Elections: All six nominees were elected with significant majorities. Broker non-votes totaled 1,229,615 for each director.
- Henry D. Cremisi, MD: 3,545,668 For; 28,391 Withheld.
- Edward Feuer: 3,542,996 For; 31,063 Withheld.
- Joy Goudie, Esq.: 3,545,643 For; 28,416 Withheld.
- Michael Feldschuh: 3,524,421 For; 49,638 Withheld.
- Jonathan Feldschuh: 3,524,421 For; 49,638 Withheld.
- Caleb DesRosiers, Esq.: 3,545,668 For; 28,391 Withheld.
- Auditor Ratification: Citrin Cooperman, LLP was ratified as the independent registered public accounting firm with 4,759,964 votes For, 28,418 Against, and 15,797 Abstain.
Guidance, Outlook, and Risks
The filing includes standard forward-looking statements regarding the impact of hiring sales staff and expanding distribution channels. Management notes that actual results may differ due to risks including post-market clinical data collection, product development, market acceptance, competitive offerings, intellectual property, and FDA regulatory actions. No specific financial guidance or unusual items were disclosed in this filing.
Key Facts for Investor Verification
- Verify the total number of shares outstanding to contextualize the voting percentages.
- Confirm the terms of the newly elected directors expire at the 2025 annual meeting.
- Review the company's most recent 10-K or 10-Q for financial performance data, as this 8-K contains no financial metrics.
- Monitor future filings for updates on the commercialization efforts and sales staff expansion mentioned in the forward-looking statements.